Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 9/20 | 0.70 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595861 | 0.91 | MARS2 (0.67) | MARS2MAPTRAB9APOLBGAA | |
| SCHEMBL23419421 | 0.86 | MARS2 (0.52) | MARS2FPR2MAPTRAB9AJAK2 | |
| SCHEMBL20596125 | 0.82 | MARS2 (1.00) | MARS2NOS3NOS1NOS2FPR2 | |
| SCHEMBL20596131 | 0.82 | MARS2 (0.56) | MARS2RAB9AKDM4EALDH1A1POLB | |
| SCHEMBL20596079 | 0.82 | MARS2 (0.68) | MARS2NOS3NOS1NOS2FPR2 | |
| SCHEMBL20595905 | 0.81 | MARS2 (0.56) | MARS2POLB | |
| SCHEMBL20595919 | 0.80 | MARS2 (0.56) | MARS2KDM4EALDH1A1POLBGAA | |
| SCHEMBL20595979 | 0.80 | MARS2 (0.56) | MARS2KDM4EALDH1A1POLB | |
| SCHEMBL20595944 | 0.78 | MARS2 (0.51) | MARS2 | |
| SCHEMBL23391426 | 0.77 | MARS2 (0.49) | MARS2MAPTRAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885NOS3 3039/4885NOS1 2180/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885NOS3 2767/4885NOS1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.